SEAS Tagged Articles

FDA says it finds no Vytorin-cancer link, but unsure

Posted: December 23, 2009 Pharmaceutical

The U.S. Food and Drug Administration announced today that it found no clear link between Merck’s blockbuster cholesterol drug Vytorin and increased risk of cancer, but it could not rule out the possibility that such a link exists. The agency

Have Vytorin’s falling sales finally stabilized?

Posted: December 5, 2008 Pharmaceutical

For a while it seemed as if sales of Merck’s blockbuster anti-cholesterol drug Vytorin would plummet into oblivion. Unfavorable and botched ENHANCE trial results, harrowing SEAS trial results, lawsuits filed on behalf of individuals and government, congressional inquiries, and so

Will FDA regulations and pre-emption silence Vytorin victims?

Posted: November 21, 2008 Pharmaceutical

Many Americans assume that the Food and Drug Administration adequately tests new drugs for safety before they go on the market and become available to the general population. If your doctor prescribes a new drug to help you lower your

Vytorin loses market strength … again

Posted: October 23, 2008 Pharmaceutical

Clinical trials haven’t been kind to Vytorin, Merck and Schering-Plough’s cholesterol brainchild. The first blow was dealt by the ENHANCE study, which showed Vytorin to be no more effective than much cheaper generic statins. Next came results of the SEAS

Merck speeds trial of new cholesterol drug

Posted: October 17, 2008 Pharmaceutical

Following Vytorin’s recent fall from its blockbuster status, Merck is ratcheting up studies of its new cholesterol fighting drug, The Washington Times reported. MK-0524A, as the new drug is called, is the subject of a study based in Oxford University

scientist cautions against dismissing Vytorin-cancer link

Posted: October 8, 2008 Pharmaceutical

Does Vytorin increase the risk of cancer death? The question seems like it would be simple to answer, yet finding the answer requires navigating through a murky labyrinth of botched test results, apparent cover-ups, possible payoffs, and a whorl of

SEAS study may link Vytorin, cancer

Posted: September 2, 2008 Pharmaceutical

Today in Munich, Germany, researchers presented all of the data from the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study to the European Society of Cardiology. The SEAS study roused concern back in July when researchers revealed a possible link